Crestline Management LP Takes $595,000 Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Crestline Management LP purchased a new position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 18,105 shares of the biopharmaceutical company’s stock, valued at approximately $595,000.

A number of other institutional investors have also recently bought and sold shares of AGIO. Envestnet Asset Management Inc. boosted its stake in shares of Agios Pharmaceuticals by 3.3% during the 4th quarter. Envestnet Asset Management Inc. now owns 24,805 shares of the biopharmaceutical company’s stock worth $815,000 after acquiring an additional 795 shares during the period. Venturi Wealth Management LLC acquired a new stake in Agios Pharmaceuticals during the 4th quarter valued at $33,000. Franklin Resources Inc. bought a new position in Agios Pharmaceuticals during the third quarter worth $1,499,000. Vanguard Group Inc. increased its holdings in shares of Agios Pharmaceuticals by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 5,631,321 shares of the biopharmaceutical company’s stock valued at $185,045,000 after purchasing an additional 85,339 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its position in shares of Agios Pharmaceuticals by 48.8% in the fourth quarter. Bank of New York Mellon Corp now owns 265,514 shares of the biopharmaceutical company’s stock valued at $8,725,000 after purchasing an additional 87,089 shares during the period.

Insider Activity

In related news, Director Jacqualyn A. Fouse sold 7,497 shares of Agios Pharmaceuticals stock in a transaction that occurred on Thursday, April 10th. The shares were sold at an average price of $25.90, for a total value of $194,172.30. Following the transaction, the director now directly owns 149,220 shares of the company’s stock, valued at $3,864,798. This trade represents a 4.78 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 4.93% of the company’s stock.

Agios Pharmaceuticals Price Performance

Shares of NASDAQ:AGIO opened at $27.32 on Friday. The business’s 50 day simple moving average is $29.23 and its 200 day simple moving average is $37.27. Agios Pharmaceuticals, Inc. has a 1 year low of $23.42 and a 1 year high of $62.58. The company has a market capitalization of $1.58 billion, a P/E ratio of 2.41 and a beta of 0.77.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.80) by $0.25. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. The company had revenue of $8.73 million for the quarter, compared to analyst estimates of $9.86 million. On average, sell-side analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Analysts Set New Price Targets

AGIO has been the topic of a number of research reports. StockNews.com upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday. Scotiabank lowered their target price on Agios Pharmaceuticals from $74.00 to $71.00 and set a “sector outperform” rating on the stock in a research note on Friday, May 2nd. Finally, HC Wainwright started coverage on Agios Pharmaceuticals in a report on Monday, February 24th. They set a “buy” rating and a $58.00 price target for the company. Five equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $56.00.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.